CompletedNCT00485849
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
Medication studyAges 6–17NetherlandsADHD
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- GroningenSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Netherlands
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00485849
- Official title
Show the full official title
An Open Label Pilot Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behavior Problems in Children and Adolescents With Autistic Spectrum Disorders
Get this study by email
Recruitment & locations
CompletedGroningen
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...